Cargando…
1558. Associations between gender identity and solicited adverse events after passive infusion of VRC01 or placebo in HVTN 704/HPTN 085
BACKGROUND: Gender minority individuals are understudied in clinical trials. Realizing the potential of HIV prevention options requires understanding product tolerability across diverse groups vulnerable to HIV acquisition. Within HVTN 704/HPTN 085, a phase 2b trial of the broadly neutralizing antib...
Autores principales: | Theodore, Deborah, Neradilek, Moni, Gillespie, Kevin, Edupuganti, Srilatha, Hinojosa, Juan Carlos, Lama, Javier R, De La Grecca, Robert, Davis, Annet, Mangini, Daniel J, Andrew, Philip, Marovich, Mary, Zwerski, Sheryl, Castor, Delivette, Roxby, Alison C, Cohen, Myron, Corey, Lawrence, Huang, Yunda, Karuna, Shelly, Sobieszczyk, Magdalena E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677518/ http://dx.doi.org/10.1093/ofid/ofad500.1393 |
Ejemplares similares
-
2896. Oral PrEP Uptake among HVTN 704/HPTN 085 Participants: Implications for the Future of Biomedical HIV Prevention Trials
por: Cantos, Valeria D, et al.
Publicado: (2023) -
Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine
por: Martin, Troy M., et al.
Publicado: (2023) -
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
por: Huang, Yunda, et al.
Publicado: (2021) -
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021) -
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)